Viewing
Opinion|Videos|May 7, 2024

Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME